Lattice-Tip Focal Ablation Catheter That Toggles Between Radiofrequency and Pulsed Field Energy to Treat Atrial Fibrillation: A First-in-Human Trial

- The tissue selectivity of pulsed field ablation (PFA) provides safety advantages over radiofrequency ablation (RFA) in treating atrial fibrillation (AF). "One-shot" PFA catheters have been shown capable of performing pulmonary vein isolation (PVI), but not flexible lesion sets such as li...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation. Arrhythmia and electrophysiology 2020-06, Vol.13 (6), p.e008718-e008718
Hauptverfasser: Reddy, Vivek Y., Anter, Elad, Rackauskas, Gediminas, Peichl, Petr, Koruth, Jacob S., Petru, Jan, Funasako, Moritoshi, Minami, Kentaro, Natale, Andrea, Jais, Pierre, Nakagawa, Hiroshi, Marinskis, Germanas, Aidietis, Audrius, Kautzner, Josef, Neuzil, Petr
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:- The tissue selectivity of pulsed field ablation (PFA) provides safety advantages over radiofrequency ablation (RFA) in treating atrial fibrillation (AF). "One-shot" PFA catheters have been shown capable of performing pulmonary vein isolation (PVI), but not flexible lesion sets such as linear lesions. A novel lattice-tip ablation catheter with a compressible 9-mm nitinol tip is able to deliver either focal RFA or PFA lesions, each in 2-5 seconds. - In a 3-center, single-arm, first-in-human trial, the 7.5-French lattice catheter was used with a custom mapping system to treat paroxysmal or persistent AF. Toggling between energy sources, point-by-point PV encirclement was performed using biphasic PFA posteriorly, and either temperature-controlled irrigated RFA or PFA anteriorly (RF/PF or PF/PF, respectively). Linear lesions were created using either PFA or RFA. - The 76-patient cohort included 55 paroxysmal and 21 persistent AF patients undergoing either RF/PF (40 patients) or PF/PF (36 patients) ablation. The PVI therapy duration time (transpiring from first to last lesion) was 22.6±8.3 min/patient, with a mean of 50.1 RF/PF lesions/patient. Linear lesions included 14 mitral (4 RF / 2 RF+PF / 8 PF), 34 LA roof (12 RF / 22 PF) and 44 CTI (36 RF / 8 PF) lines, with therapy duration times of 5.1±3.5, 1.8±2.3 and 2.4±2.1 min/patient, respectively. All lesion sets were acutely successful, using 4.7±3.5 min of fluoroscopy. There were no device-related complications, including no strokes. Post-procedure esophagogastroduodenoscopy revealed minor mucosal thermal injury in 2 of 36 RF/PF and 0 of 24 PF/PF patients. Post-procedure brain MRI revealed DWI+/FLAIR- and DWI+/FLAIR+ asymptomatic lesions in 5 and 3 of 51 patients, respectively. - A novel lattice-tip catheter could safely and rapidly ablate AF using either a combined RF/PF approach (capitalizing on the safety of PFA and the years of experience with radiofrequency energy) or an entirely PF approach.
ISSN:1941-3084
1941-3149
1941-3084
DOI:10.1161/CIRCEP.120.008718